Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

Nat Med. 2020 Apr;26(4):498-501. doi: 10.1038/s41591-020-0774-y. Epub 2020 Mar 23.

Abstract

We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • AIDS Vaccines* / administration & dosage
  • AIDS Vaccines* / adverse effects
  • AIDS Vaccines* / immunology
  • Acute Disease
  • Adolescent
  • Adult
  • Anti-Retroviral Agents / therapeutic use*
  • Double-Blind Method
  • Drug Substitution / adverse effects
  • Female
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • HIV Infections / virology
  • HIV-1 / drug effects
  • HIV-1 / immunology*
  • Humans
  • Immunogenicity, Vaccine* / drug effects
  • Male
  • Middle Aged
  • Placebos
  • Thailand
  • Treatment Outcome
  • Viral Load* / drug effects
  • Viral Vaccines* / administration & dosage
  • Viral Vaccines* / adverse effects
  • Viral Vaccines* / immunology
  • Withholding Treatment
  • Young Adult

Substances

  • AIDS Vaccines
  • Anti-Retroviral Agents
  • MVA vaccine
  • Placebos
  • Viral Vaccines

Associated data

  • ClinicalTrials.gov/NCT02919306